Goodwin

Goodwin’s signature technology expertise is a big draw for start-ups, while it also leverages a dominant life sciences offering that ‘provides everything a biotech company could need’. Alongside its company-side credentials, the group maintains close links with investors and it routinely advises venture capital funds on fundraisings, investments, and exits. From Boston, Mitch Bloom steers the life science practice and specializes in advising public and private life sciences companies and investors on financings, M&A, and public offerings. The technology and emerging companies team is co-led by Boston-based duo John Egan and Kenneth Gordon, together with Silicon Valley’s Craig Schmitz , all of whom act for an array of start-ups, growth companies, and investors. Other contacts in Boston include Bill Schnoor, who, as previous head of the London office, is recommended for cross-border transactions involving the technology and life sciences sectors; Danielle Lauzon, who is recognized for her cutting-edge expertise in the life sciences field; and William Collins, who excels in matters involving the biotechnology, pharmaceuticals, and medical devices spheres. In Silicon Valley, Caine Moss focuses on supporting software, AI, internet, and financial services companies through all stages of their growth.